Citigroup upgraded shares of Bradmer Pharmaceuticals (TSE:GLX – Free Report) to a hold rating in a report published on Tuesday,Zacks.com reports.
GLX has been the subject of several other reports. ATB Cormark Capital Markets downgraded Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a research note on Thursday, February 5th. Citizens Jmp upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th. Five investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Bradmer Pharmaceuticals has a consensus rating of “Buy”.
Get Our Latest Stock Analysis on GLX
Bradmer Pharmaceuticals Price Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
